Anakinra, a natural antagonist for the IL-1 Receptor, is effective in treating patients with sJIA or AOSD who develop MAS (5, 53, 54), with a mechanism involving a reduction in the processing of precursor IL-18 into an active cytokine (55). The gene discussed is IL18; the disease is macrophage activation syndrome.